FMP
REGENXBIO Inc.
RGNX
NASDAQ
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II;RGX-111, which is in Phase I/II clinical trial for treating mucopolysaccharidosis type I;RGX-181 which is in pre clinic stage for the treatment of late-infantile neuronal ceroid lipofuscinosis type II disease;RGX-202, to treat Duchenne muscular dystrophy which is in phase I/II clinical trial; and RGX-381, to treat the ocular manifestations of CLN2 disease which is in preclinical stage. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop novel gene therapies. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.
6.33 USD
0.44 (6.95%)
Operating Data
Year
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Revenue
154.57M
470.35M
112.72M
90.24M
83.33M
82.57M
81.82M
81.07M
80.34M
79.61M
Revenue %
-
204.3
-76.03
-19.94
-7.66
-0.91
-0.91
-0.91
-0.91
Ebitda
-96.83M
169.54M
-244.24M
-239.46M
-198.23M
-53.93M
-53.44M
-52.96M
-52.48M
-52M
Ebitda %
-62.65
36.05
-216.67
-265.36
-237.89
-65.32
-65.32
-65.32
-65.32
Ebit
-105.24M
159.98M
-257.15M
-256.78M
-214.44M
-55.17M
-54.67M
-54.17M
-53.68M
-53.19M
Ebit %
-68.09
34.01
-228.12
-284.55
-257.35
-66.81
-66.81
-66.81
-66.81
Depreciation
8.41M
9.56M
12.91M
17.32M
16.21M
9.51M
9.42M
9.34M
9.25M
9.17M
Depreciation %
5.44
2.03
11.45
19.19
19.46
11.52
11.52
11.52
11.52
EBIT (Operating profit)(Operating income)(Operating earning) = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT) EBIT = (1*) (2*) -> operating process (leverage -> interest -> EBT -> tax -> net Income) EBITDA = GROSS MARGIN (REVENUE - COGS) - OPERATING EXPENSES (R&D, RENT) + Depreciation + amortization EBITA = (1*) (2*) (3*) (4*) company's CURRENT operating profitability (i.e., how much profit it makes with its present assets and its operations on the products it produces and sells, as well as providing a proxy for cash flow) -> performance of a company (1*) discounting the effects of interest payments from different forms of financing (by ignoring interest payments), (2*) political jurisdictions (by ignoring tax), collections of assets (by ignoring depreciation of assets), and different takeover histories (by ignoring amortization often stemming from goodwill) (3*) collections of assets (by ignoring depreciation of assets) (4*) different takeover histories (by ignoring amortization often stemming from goodwill)
